21
David M Goldenberg, Hans J Hansen, Zhengxing Qu: Monoclonal antibody hPAM4. Immunomedics, Faegre & Benson, October 16, 2007: US07282567 (43 worldwide citation)

This invention relates to monovalent and multivalent, monospecific antibodies and to multivalent, multispecific antibodies. One embodiment of these antibodies has one or more identical binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodi ...


22
Chien Hsing Chang, David M Goldenberg, William J McBride, Edmund A Rossi: Stably tethered structures of defined compositions with multiple functions or binding specificities. IBC Pharmaceuticals, Richard A Nakashima, January 18, 2011: US07871622 (38 worldwide citation)

The present invention concerns methods and compositions for stably tethered structures of defined compositions with multiple functionalities and/or binding specificities. Particular embodiments concern stably tethered structures comprising a homodimer of a first monomer, comprising a dimerization an ...


23
David M Goldenberg, Hans J Hansen: Antibody therapy. Immunomedics, Richard A Nakashima, February 16, 2010: US07662378 (38 worldwide citation)

The present invention provides a composition comprising naked humanized, chimeric, and human anti-CEA antibodies and a therapeutic agent, which is useful for treatment of CEA expressing cancers and other diseases, and methods of use in treatment using this composition.


24
Chien Hsing Chang, David M Goldenberg, Edmund A Rossi: Multivalent immunoglobulin-based bioactive assemblies. IBC Pharmaceuticals, Richard A Nakashima, December 28, 2010: US07858070 (37 worldwide citation)

The present invention concerns methods and compositions for stably tethered structures of defined compositions, which may have multiple functionalities and/or binding specificities. Preferred embodiments concern hexameric stably tethered structures comprising one or more IgG antibody fragments and w ...


25
David M Goldenberg, Hans J Hansen: Immunotherapy of autoimmune disorders using antibodies which target B-cells. Immunomedics, Rossi Kimms & McDowell, January 5, 2010: US07641901 (37 worldwide citation)

Antibodies that bind with a B-cell antigen provide an effective means to treat autoimmune disorders. Antibodies and fragments, which may be conjugated or naked, are used alone or in multimodal therapies. The antibodies may be bispecific antibodies which may be produced recombinantly as fusion protei ...


26
Chien Hsing Chang, David M Goldenberg, William J McBride, Edmund A Rossi: Methods and compositions for generating bioactive assemblies of increased complexity and uses. IBC Pharmaceuticals, Richard A Nakashima, March 15, 2011: US07906121 (36 worldwide citation)

The present invention concerns methods and compositions for making and using bioactive assemblies of defined compositions, which may have multiple functionalities and/or binding specificities. In particular embodiments, the bioactive assembly is formed using dock-and-lock (DNL) methodology, which ta ...


27
David M Goldenberg: Immunotherapy of B-cell malignancies using anti-CD22 antibodies. Immunomedics, Rossi Kimms & McDowell, January 31, 2012: US08105596 (36 worldwide citation)

B-cell malignancies, such as the B-cell subtype of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to various forms of treatment is mixed. Traditional methods of treating B-cell malignancies, including che ...


28
David M Goldenberg, Hans J Hansen: Chimeric antibody for detection and therapy of infectious and inflammatory lesions. Immunomedics, Foley & Lardner, October 14, 1997: US05677427 (36 worldwide citation)

A chimeric antibody-agent conjugate for targeting foci of leukocyte accretion comprises a recombinant chimera having an antigen-binding hypervariable region which binds specifically to granulocytes, and a constant region of a human immunoglobulin having an Fc portion with high affinity for receptors ...


29
Chien Hsing Chang, David M Goldenberg, William J McBride, Edmund A Rossi: Dimeric alpha interferon pegylated site-specifically shows enhanced and prolonged efficacy in vivo. IBC Pharmaceuticals, Richard A Nakashima, August 23, 2011: US08003111 (34 worldwide citation)

The present invention concerns methods and compositions for forming PEGylated complexes of defined stoichiometry and structure. In preferred embodiments, the PEGylated complex is formed using dock-and-lock technology, by attaching a therapeutic agent to a DDD sequence and attaching a PEG moiety to a ...


30
Chien Hsing Chang, David M Goldenberg, Edmund A Rossi: Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology. IBC Pharmaceuticals, Richard A Nakashima, March 15, 2011: US07906118 (34 worldwide citation)

The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the cytokine-MAb DNL complex comprises an IgG antibody attached to two AD (anchor domain) moieties and four cytokines, each attached to a DDD (doc ...